Castor Blog

Electronic Clinical Outcome Assessment (ECOA) and electronic Patient Reported Outcomes (ePRO) represent far more than digital surveys in clinical trials. This foundational guide explains the four ECOA components (ePRO, eClinRO, eObsRO, ePerfO), why BYOD delivers superior patient compliance over provisioned devices, and the hidden complexities of copyrighted instruments approval. Discover why commercial trials demand specialized expertise in linguistic validation, regulatory compliance, and measurement equivalence that academic research often overlooks. Essential knowledge for clinical operations professionals planning their next patient outcome strategy.

Electronic clinical outcome assessments (eCOA) were supposed to solve data quality and amplify the patient voice. Yet missing baseline data, poor site readiness, and disorganized planning still derail trials. Experts from Castor, Kielo, and RTI Health Solutions share where the true failures occur — and what you can do to prevent them. With a focus on practical, experience-based advice, this article breaks down why eCOA problems persist and how sponsors and CROs can build simpler, more resilient study designs that actually work in the real world.

Gameto proves you don’t need a large CRO or a floor of data managers to run complex global trials. With only three people in clinical operations, the biotech launched nine IVF studies across Peru, Mexico, Australia, and the United States, built full Spanish CRFs in three weeks, and delivered the 38-patient dataset that moved Fertilo straight into FDA Phase 3. Castor EDC gave the team version control, multilingual forms, and audit trails—without slowing them down. If you care about lean, regulator-ready execution, this case study is worth ten minutes of your time.

Sword Health treated clinical evidence as a strategy, not a one-time study. Over ten years it used clinical research for three jobs in sequence: to overcome clinician skepticism, to establish digital care as a new standard, and to prove cost-effectiveness for reimbursement. In this session with Castor’s Derk Arts, Sword CMO Fernando Correia explains how the company built a real-world dataset of more than 200,000 low back pain patients on its own systems, ran two randomized trials on Castor comparing digital and in-person care, and designed studies that hold up in the real world. Watch the conversation on demand.

Explore how Castor’s 2025 updates reduce site burden and boost compliance through scalable, flexible DTP workflows.

Hard truths on scaling biotech: data isn’t enough, CEOs matter, and funding follows story—not science.

Poor comprehension of informed consent disrupts trials. Here’s how to fix it—with data, tech, and actual patient understanding.

Adopt AI in clinical research with confidence using a risk-based framework that ensures privacy, security, and regulatory alignment.

What a Museum of Medicine can teach us about trials, trust, and how the public sees (or doesn’t see) biomedical progress.